Enterprise Value

22.32B

Cash

2.058B

Avg Qtr Burn

-118.2M

Short % of Float

4.26%

Insider Ownership

0.34%

Institutional Own.

97.71%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
AMVUTTRA (Vutrisiran) Details
Transthyretin amyloidosis

Approved

Update

OXLUMO® (lumasiran) Details
Primary hyperoxaluria

Approved

Quarterly sales

Leqvio® (inclisiran) Details
Transthyretin amyloidosis

Approved

Quarterly sales

ONPATTRO® (Patisiran) Details
Transthyretin amyloidosis

PDUFA

Approval decision

Phase 3

Data readout

Zilebesiran (ALN-AGT) Details
Metabolic disorder, Pulmonary arterial hypertension

Phase 2

Data readout

Phase 2

Data readout

ALN-HSD Details
Non-alcoholic steatohepatitis

Phase 1

Data readout

ALN-PNP Details
Non-alcoholic steatohepatitis

Phase 1

Update

ALN-APP Details
Alzheimer's disease, Cerebral Amyloid Angiopathy

Phase 1

Update

ALN-TTRsc04 Details
Transthyretin amyloidosis

Phase 1a

Data readout

ALN-KHK Details
Type 2 diabetes

Phase 1a

Data readout

ALN-XDH Details
Arthritis, Chronic refractory gout

Failed

Discontinued

Failed

Discontinued